Amorphous HMG-CoA reductase inhibitors of desired particle size

Details Amorphous HMG-CoA reductase inhibitors of desired particle size Amorphous HMG-CoA reductase inhibitors of desired particle size

2007-06-12

2007-06-12

Saeed, Kamal A. (Department: 1626)

Organic compounds -- part of the class 532-570 series

Organic compounds

Heterocyclic carbon compounds containing a hetero ring...

Reexamination Certificate

active

10483553

ABSTRACT:
In one aspect, the invention provides a process for the preparation of an amorphous HMG-CoA reductase inhibitor and hydrates thereof of desired particle size, which comprises: dissolving the HMG-CoA reductase inhibitor in a hydroxylic solvent, and removing the solvent by freeze-drying.

REFERENCES:
patent: 5273995 (1993-12-01), Roth
patent: 6274740 (2001-08-01), Lin et al.
patent: 6528661 (2003-03-01), Niddam et al.
patent: 6646133 (2003-11-01), Greff et al.
patent: 2002/0099224 (2002-07-01), Niddam et al.
patent: 2003/0114685 (2003-06-01), Niddam-Hildesheim et al.
patent: 2003/0175338 (2003-09-01), Singh et al.
patent: 2005/0119343 (2005-06-01), Tillyer et al.
patent: WO 97/03958 (1997-02-01), None
patent: WO 97/03960 (1997-02-01), None
patent: WO 00/53566 (2000-09-01), None
patent: WO0053566 (2000-09-01), None
patent: WO 01/10813 (2001-02-01), None
patent: WO 01/28999 (2001-04-01), None
patent: WO 01/42209 (2001-06-01), None
patent: WO 02/43667 (2002-06-01), None
patent: WO 03/004450 (2003-01-01), None
patent: WO 03/004455 (2003-01-01), None
patent: WO 03/004456 (2003-01-01), None
patent: WO 03/016317 (2003-02-01), None
International Search Report for corresponding PCT application PCT/IN02/00045 (WO 03/078379).
Oehrlein R et al., “Chemoenzymatic approach to statin side-chain building blocks” Advanced Synthesis Catalysis (2003), 345 (6+7), 713-715.
Woo et al., “Atorvastatin, an HMG-CoA reductase inhibitor and effective lipid-regulating agent. Part III. Syntheses of [2H5]-, [13C8], and [13C7, 15N] atorvastatin and their application in metabolic and pharmacokinetic studies”, Journal of Labeled Compounds Radiopharmaceuticals (1999), 42(2), 135-145.
Lee et al., “Atorvastatin, an HMG-CoA reductase inhibitor and effective lipid-regulating agent. Part II. Synthesis of side chain-labeled [14C] atorvastatin”, Journal of Labeled Compounds Radiopharmaceuticals (1999), 42(2), 129-133.
Woo et al., “Atorvastatin, an HMG-CoA reductase inhibitor and effective lipid-regulating agent. Part I. Synthesis of ring-labeled [14C] atorvastatin”, Journal of Labeled Compounds Radiopharmaceuticals (1999), 42(2), 121-127.
Radl et al., “An improved synthesis of 1,1-dimethylethyl-6-cyanomethyl-2,2-dimethyl-1,3-dioxane-4-acetate, a key intermediate for atorvastatin synthesis”, Tetrahedron Letters (2002), 43(11), 2087-2090.
Manzoni et al., “Biosynthesis and biotechnological production of statins by filamentous fungi and application of these cholesterol-lowering drugs”, Applied Microbiology and Biotechnology (2002), 58(5), 555-564.
Roth, Bruce D., “The discovery and development of atorvastatin, a potent novel hypolipidemic agent”, Progess in Medicinal Chemistry (2002), 40, 1-22.
Wierzbicki, Anthony S., “Atorvastatin”, Expert Opinion on Pharmacotherapy (2001), 2(5), 819-830.
Graul et al., “Atorvastatin calcium”, Drugs of the future (1997), 22(9), 956-968.
Baumann et al., “The convergent synthesis of CI-981, an optically active, highly potent, tissue-selective inhibitor of HMG-CoA reductase”, Tetrahedron Letters (1992), 33(17), 2283-2284.

Affiliated with

Also associated with

Rating

Amorphous HMG-CoA reductase inhibitors of desired particle size does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Amorphous HMG-CoA reductase inhibitors of desired particle size, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amorphous HMG-CoA reductase inhibitors of desired particle size will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3864120